Dare Bioscience
DARE
Dare Bioscience (DARE) earnings history
Most recent quarter
- Fiscal period
- Q2 2026
- Period end
- Jun 30, 2026
- EPS actual
- −$0.20
- EPS estimate
- −$0.30
- EPS surprise
- +32.59%
- Revenue surprise
- +11150.51%
- Revenue
- $187,546.00
- Revenue estimate
- $1,667.00
- Reported
- Aug 13, 2026
Earnings history
| Period | Reported | EPS estimate | EPS actual | Surprise | Revenue | Filing |
|---|---|---|---|---|---|---|
| Q2 2026 | Aug 13, 2026 | −$0.30 | −$0.20 | +32.59% | $187,546.00 | SEC |
| Q1 2026 | May 14, 2026 | −$0.31 | −$0.20 | +34.43% | $152,455.00 | SEC |
| Q4 2025 | Mar 26, 2026 | −$0.44 | $0.03 | +106.82% | $1.0M | SEC |
| Q3 2025 | Nov 13, 2025 | −$0.38 | −$0.28 | +27.08% | $2,262.00 | SEC |
| Q2 2025 | Aug 14, 2025 | −$0.58 | −$0.45 | +22.45% | −$21,172.00 | SEC |
| Q1 2025 | May 13, 2025 | −$0.58 | −$0.50 | +13.79% | $25,427.00 | SEC |
| Q3 2024 | Nov 14, 2024 | −$0.69 | −$0.55 | +19.71% | $41,691.00 | SEC |
| Q2 2024 | Aug 12, 2024 | −$0.04 | $1.52 | +3997.44% | $22,438.00 | SEC |
| Q1 2024 | May 14, 2024 | −$0.72 | −$0.84 | −16.67% | $9,302.00 | SEC |
| Q4 2023 | Mar 28, 2024 | −$1.08 | −$0.84 | +22.22% | $1.8M | SEC |
| Q3 2023 | Nov 9, 2023 | −$1.18 | −$1.09 | +6.99% | $1.0M | SEC |
| Q2 2023 | Aug 10, 2023 | −$1.18 | −$1.20 | −1.69% | $0.00 | SEC |
| Q1 2023 | May 11, 2023 | −$1.20 | −$1.08 | +10.00% | $0.00 | SEC |
| Q4 2022 | Mar 30, 2023 | −$1.64 | −$2.28 | −39.02% | $0.00 | SEC |
| Q3 2022 | Nov 10, 2022 | −$1.40 | −$0.96 | +31.43% | $0.00 | SEC |
| Q2 2022 | Aug 9, 2022 | −$0.76 | $0.00 | +100.00% | $10.0M | — |
| Q1 2022 | May 12, 2022 | −$1.71 | −$1.20 | +29.82% | $0.00 | SEC |
| Q4 2021 | Mar 31, 2022 | −$1.75 | −$1.32 | +24.66% | $0.00 | SEC |
| Q3 2021 | Nov 10, 2021 | −$1.53 | −$2.16 | −41.18% | $0.00 | — |
| Q2 2021 | Aug 12, 2021 | −$1.89 | −$2.16 | −14.29% | $0.00 | — |
Quarterly revenue
Frequently asked questions
When did Dare Bioscience (DARE) last report earnings?
Dare Bioscience last reported on Aug 13, 2026, covering fiscal Q2 2026.
Did DARE beat earnings estimates?
Yes. Dare Bioscience reported EPS of −$0.20 for Q2 2026 against a −$0.30 estimate — a 32.59% beat.
How much revenue did DARE report last quarter?
Dare Bioscience reported $187,546.00 in revenue for Q2 2026, against a consensus estimate of $1,667.00.
Earnings figures may be restated, revised or corrected by the issuer. Past results do not indicate future performance.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.